RxDoctor Payments Data

Julia Clift, APRN

Family · Little Rock, ARNPI 1649874736

Payments from drug & device makers

$4,614in general payments, 2019–2025

Across 222 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$765
  • Amgen$644
  • GSK$301
  • AstraZeneca$250
  • Novartis$247
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,55499%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,614 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$798
Medicare patients
29
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept38$274,438
RinvoqUpadacitinib25$153,208
Hydroxychloroquine Sulfate248$10,103
Colchicine79$6,940
Mycophenolate Mofetil17$5,984
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen160$3,666
Leflunomide46$2,369
Gabapentin122$1,966
Diclofenac Sodium60$1,882
Pregabalin62$1,791
Azathioprine32$1,780
MethotrexateMethotrexate Sodium101$1,183
Febuxostat13$972
Sulfasalazine51$918
Prednisone139$891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,001$153,20825 claims
Scilex Pharmaceuticals Inc.Colchicine$46$6,94079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →